B-hTSLP/hTSLPR mice plus_Biocytogen Pharmaceuticals (Beijing) Co., Ltd._Biocytogen, drug development, antibody discovery

Please input keywords

Order

*Country

United States

China

France

Germany

Netherlands

United Kingdom

Japan

South Korea

Israel

Australia

Hong Kong, China

New Zealand

Russia

Singapore

Taiwan, China

India

Aland Islands

Albania

Algeria

American Samoa

Andorra

Angola

Anguilla

Antarctica

Antigua & Barbuda

Argentina

Armenia

Aruba

Ascension Island

Austria

Azerbaijan

Bahamas

Bahrain

Bangladesh

Barbados

Belarus

Belgium

Belize

Benin

Bermuda

Bhutan

Bolivia

Bosnia & Herzegovina

Botswana

Brazil

British Indian Ocean Territory

British Virgin Islands

Brunei

Bulgaria

Burkina Faso

Burundi

Cambodia

Cameroon

Canada

Canary Islands

Cape Verde

Caribbean Netherlands

Cayman Islands

Central African Republic

Ceuta & Melilla

Chad

Chile

Christmas Island

Cocos (Keeling) Islands

Colombia

Comoros

Congo - Brazzaville

Congo - Kinshasa

Cook Islands

Costa Rica

Côte d’Ivoire

Croatia

Cuba

Curaçao

Cyprus

Czechia

Denmark

Diego Garcia

Djibouti

Dominica

Dominican Republic

Ecuador

Egypt

El Salvador

Equatorial Guinea

Eritrea

Estonia

Ethiopia

Falkland Islands

Faroe Islands

Fiji

Finland

French Guiana

French Polynesia

French Southern Territories

Gabon

Gambia

Georgia

Ghana

Gibraltar

Greece

Greenland

Grenada

Guadeloupe

Guam

Guatemala

Guernsey

Guinea

Guinea-Bissau

Guyana

Haiti

Honduras

Hungary

Iceland

Indonesia

Iran

Iraq

Ireland

Isle of Man

Italy

Jamaica

Jersey

Jordan

Kazakhstan

Kenya

Kiribati

Kosovo

Kuwait

Kyrgyzstan

Laos

Latvia

Lebanon

Lesotho

Liberia

Libya

Liechtenstein

Lithuania

Luxembourg

Macau, China

Macedonia

Madagascar

Malawi

Malaysia

Maldives

Mali

Malta

Marshall Islands

Martinique

Mauritania

Mauritius

Mayotte

Mexico

Micronesia

Moldova

Monaco

Mongolia

Montenegro

Montserrat

Morocco

Mozambique

Myanmar (Burma)

Namibia

Nauru

Nepal

New Caledonia

Nicaragua

Niger

Nigeria

Niue

Norfolk Island

North Korea

Northern Mariana Islands

Norway

Oman

Pakistan

Palau

Palestinian Territories

Panama

Papua New Guinea

Paraguay

Peru

Philippines

Pitcairn Islands

Poland

Portugal

Puerto Rico

Qatar

Réunion

Romania

Rwanda

Samoa

San Marino

São Tomé & Príncipe

Saudi Arabia

Senegal

Serbia

Seychelles

Sierra Leone

Sint Maarten

Slovakia

Slovenia

Solomon Islands

Somalia

South Africa

South Georgia & South Sandwich Islands

South Sudan

Spain

Sri Lanka

St. Barthélemy

St. Helena

St. Kitts & Nevis

St. Lucia

St. Martin

St. Pierre & Miquelon

St. Vincent & Grenadines

Sudan

Suriname

Svalbard & Jan Mayen

Swaziland

Sweden

Switzerland

Syria

Tajikistan

Tanzania

Thailand

Timor-Leste

Togo

Tokelau

Tonga

Trinidad & Tobago

Tristan da Cunha

Tunisia

Turkey

Turkmenistan

Turks & Caicos Islands

Tuvalu

U.S. Outlying Islands

U.S. Virgin Islands

Uganda

Ukraine

United Arab Emirates

United Nations

Uruguay

Uzbekistan

Vanuatu

Vatican City

Venezuela

Vietnam

Wallis & Futuna

Western Sahara

Yemen

Zambia

Zimbabwe

*Province

*City

*Name

*Telephone

*Company

*Position

*Email

*Verification code

*Verification Code

Home

Animal models

Animal / cell resources

Humanized Mouse Models

Cytokine Humanized Mice

Text

B-hTSLP/hTSLPR mice plus

Strain name	Non-disclosure	Common Name	B-hTSLP/hTSLPR mice plus
Background	C57BL/6	Catalog number	112744
Aliases	TSLP: NA;CRLF2: CRL2Y, TSLPR

Protein expression analysis-TSLP

from clipboard

Strain specific TSLP expression analysis in wild type C57BL/6 mice, homozygous B-hTSLP/hTSLPR mice and B-hTSLP/hTSLPR mice plus by ELISA. Calcipotriol (MC903) was dissolved in ethanol and topically applied on ears of wild type C57BL/6 mice, homozygous B-hTSLP/hTSLPR mice and B-hTSLP/hTSLPR mice plus for 7 days. Ear grinding supernatant from the three strain of mice were analyzed by ELISA. Mouse TSLP was only detectable in wild type C57BL/6 mice. Human TSLP was detectable in homozygous B-hTSLP/hTSLPR mice and B-hTSLP/hTSLPR mice plus but not in wild type mice.

Protein expression analysis of TSLPR in spleen

from clipboard

Data from Huabo Biopharm Co. Ltd.

Mouse and human TSLPR expression analysis in splenocytes. Splenocytes were collected from wild type C57BL/6 mice, homozygous B-hTSLP/hTSLPR mice and B-hTSLP/hTSLPR mice plus. TSLPR expressed on cDC, pDC and non DCs were analyzed by flow cytometry with species-specific anti-TSLPR antibody. Mouse TSLPR were detectable on cDC, pDC and non DCs of wild type C57BL/6 mice, but not on the cells of TSLPR humanized mice. Human TSLPR was detectable on cDC, pDC and non DCs of B-hTSLP/hTSLPR mice and B-hTSLP/hTSLPR mice plus, but not on the cells of wild type C57BL/6 mice.

Protein expression analysis of TSLPR in bone marrow

from clipboard

Data from Huabo Biopharm Co. Ltd.

Mouse and human TSLPR expression analysis in bone marrow. Bone marrow cells were collected from wild type C57BL/6 mice, homozygous B-hTSLP/hTSLPR mice and B-hTSLP/hTSLPR mice plus. TSLPR expressed on bone marrow cells were analyzed by flow cytometry with species-specific anti-TSLPR antibody. Mouse TSLPR were detectable on cDC, pDC and non DCs in wild type C57BL/6 mice, but not on the cells of TSLPR humanized mice. Human TSLPR was detectable on cDC, pDC and non DCs of B-hTSLP/hTSLPR mice and B-hTSLP/hTSLPR mice plus, but not on the cells of wild type C57BL/6 mice.

Protein expression analysis of hTSLPR in cDC1 from bone marrow

from clipboard

Data from Huabo Biopharm Co. Ltd.

Human TSLPR expression analysis in cDC1 from bone marrow. Bone marrow were collected from wild type C57BL/6 mice, homozygous B-hTSLP/hTSLPR mice and B-hTSLP/hTSLPR mice plus. Human TSLPR expressed on cDC1 were analyzed by flow cytometry with species-specific antibodies. Human TSLPR was highly expressed on the cDC1 in B-hTSLP/hTSLPR mice and B-hTSLP/hTSLPR mice plus.

Analysis of leukocytes cell subpopulation in spleen

from clipboard

Analysis of spleen leukocyte subpopulations by flow cytometry. Splenocytes were isolated from female C57BL/6 and B-hTSLP/hTSLPR mice plus (n=3, 9-week-old). Flow cytometry analysis of the splenocytes was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live cells were gated for the CD45+ population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of T cells, B cells, NK cells, DCs, neutrophils, monocytes and macrophages in homozygous B-hTSLP/hTSLPR mice plus were similar to those in the C57BL/6 mice, demonstrating that TSLP，TSLPR and IL7R humanized does not change the overall development, differentiation or distribution of these cell types in splenocytes. Values are expressed as mean ± SEM.

Analysis of T cell subpopulation in spleen

from clipboard

Analysis of spleen T cell subpopulations by flow cytometry. Splenocytes were isolated from female C57BL/6 and B-hTSLP/hTSLPR mice plus (n=3, 9-week-old). Flow cytometry analysis of the splenocytes was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live CD45+ cells were gated for CD3+ T cell population and used for further analysis as indicated here. B. Results of FACS analysis. The percent of CD4+ T cells, CD8+ T cells and Tregs in homozygous B-hTSLP/hTSLPR mice plus were similar to those in the C57BL/6 mice, demonstrating that TSLP，TSLPR and IL7R humanized does not change the overall development, differentiation or distribution of these T cell types in spleen. Values are expressed as mean ± SEM.

Analysis of leukocytes cell subpopulation in blood

from clipboard

Analysis of blood leukocyte subpopulations by flow cytometry. Blood were isolated from female C57BL/6 and B-hTSLP/hTSLPR mice plus (n=3, 9-week-old). Flow cytometry analysis of the blood was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live cells were gated for the CD45+ population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of T cells, B cells, NK cells, dendritic cells, neutrophils, monocytes and macrophages in homozygous B-hTSLP/hTSLPR mice plus were similar to those in the C57BL/6 mice, demonstrating that TSLP，TSLPR and IL7R humanized does not change the overall development, differentiation or distribution of these cell types in blood. Values are expressed as mean ± SEM.

Analysis of T cell subpopulation in blood

from clipboard

Analysis of blood T cell subpopulations by flow cytometry. Blood were isolated from female C57BL/6 and B-hTSLP/hTSLPR mice plus (n=3, 9-week-old). Flow cytometry analysis of the blood was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live CD45+ cells were gated for CD3+ T cell population and used for further analysis as indicated here. B. Results of FACS analysis. The percent of CD4+ T cells, CD8+ T cells and Tregs in homozygous B-hTSLP/hTSLPR mice plus were similar to those in the C57BL/6 mice, demonstrating that TSLP，TSLPR and IL7R humanized does not change the overall development, differentiation or distribution of these T cell types in blood. Values are expressed as mean ± SEM.

Analysis of leukocytes cell subpopulation in lymph node

from clipboard

Analysis of lymph node leukocyte subpopulations by flow cytometry. Lymph nodes were isolated from female C57BL/6 and B-hTSLP/hTSLPR mice plus (n=3, 9-week-old). Flow cytometry analysis of the lymph node was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live cells were gated for the CD45+ population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of T cells, B cells, NK cells, dendritic cells, neutrophils, monocytes and macrophages in homozygous B-hTSLP/hTSLPR mice plus were similar to those in the C57BL/6 mice, demonstrating that TSLP, TSLPR and IL7R humanized does not change the overall development, differentiation or distribution of these cell types in lymph node. Values are expressed as mean ± SEM.

Analysis of T cell subpopulation in lymph node

from clipboard

Analysis of lymph node T cell subpopulations by flow cytometry. Lymph nodes were isolated from female C57BL/6 and B-hTSLP/hTSLPR mice plus (n=3, 9-week-old). Flow cytometry analysis of the lymph node was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live CD45+ cells were gated for CD3+ T cell population and used for further analysis as indicated here. B. Results of FACS analysis. The percent of CD4+ T cells, CD8+ T cells and Tregs in homozygous B-hTSLP/hTSLPR mice plus were similar to those in the C57BL/6 mice, demonstrating that TSLP, TSLPR and IL7R humanized does not change the overall development, differentiation or distribution of these T cell types in lymph node. Values are expressed as mean ± SEM.

Analysis of leukocytes cell subpopulation in thymus

from clipboard

Analysis of thymus leukocyte subpopulations by flow cytometry. Thymuses were isolated from female C57BL/6 and B-hTSLP/hTSLPR mice plus (n=3, 9-week-old). Flow cytometry analysis of the thymus was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live cells were gated for the CD45+ population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of T cells, B cells, NK cells, dendritic cells, neutrophils, monocytes and macrophages in homozygous B-hTSLP/hTSLPR mice plus were similar to those in the C57BL/6 mice, demonstrating that TSLP, TSLPR and IL7R humanized does not change the overall development, differentiation or distribution of these cell types in thymus. Values are expressed as mean ± SEM.

Analysis of T cell subpopulation in thymus

from clipboard

Analysis of thymus T cell subpopulations by flow cytometry. Thymuses were isolated from female C57BL/6 and B-hTSLP/hTSLPR mice plus (n=3, 9-week-old). Flow cytometry analysis of the thymus was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live CD45+ cells were gated for CD3+ T cell population and used for further analysis as indicated here. B. Results of FACS analysis. The percent of CD4+ T cells, CD8+ T cells and Tregs in homozygous B-hTSLP/hTSLPR mice plus were similar to those in the C57BL/6 mice, demonstrating that TSLP, TSLPR and IL7R humanized does not change the overall development, differentiation or distribution of these T cell types in thymus. Values are expressed as mean ± SEM.

Functional analysis

from clipboard

Data from Huabo Biopharm Co. Ltd.

Mouse TARC was respectively induced with human TSLP and mouse TSLP in wild type C57BL/6 mice, homozygous B-hTSLP/hTSLPR mice and B-hTSLP/hTSLPR mice plus. Dendritic cells were respectively induced with FLT3L from bone marrow of the three strains and stimulated with human TSLP or mouse TSLP in vitro. Concentration of mouse TARC secreted from DCs was assayed by ELISA. Mouse TARC was successfully induced with human TSLP, but not mouse TSLP in homozygous B-hTSLP/hTSLPR mice and B-hTSLP/hTSLPR mice plus. The level of mTARC in B-hTSLP/hTSLPR mice plus was higher than that in B-hTSLP/hTSLPR mice plus. Meanwhile mouse TARC was successfully induced with mouse TSLP, but not human TSLP in wild-type C57BL/6 mice. Results indicated that TSLP and TSLPR are not cross-reactive between mouse and human. Human TSLP can activate the dendritic cells of B-hTSLP/hTSLPR mice and B-hTSLP/hTSLPR mice plus.

Growth curve

from clipboard

Growth curve of B-hTSLP/hTSLPR mice plus. Eight weeks old of mice were grouped (10 males and 10 females, respectively). Body weight was measured on the same day of every week and lasted for 12 weeks. The lowest and highest values of mouse body weight in the table were calculated from the mean ± SD. The growth curve conforms to the normal distribution and the probability of random error falling within ± SD is 68%.

Hematology analysis

from clipboard

Complete blood count (CBC) of B-hTSLP/hTSLPR mice plus. Values are expressed as mean ± SD.

Biochemistry analysis

from clipboard

Blood biochemical test of B-hTSLP/hTSLPR mice plus. Values are expressed as mean ± SD.

Gross anatomy of female B-hTSLP/hTSLPR mice plus

from clipboard

The organs of female B-hTSLP/hTSLPR mice plus (12-week-old, n=10).

Gross anatomy of male B-hTSLP/hTSLPR mice plus

from clipboard

The organs of male B-hTSLP/hTSLPR mice plus (12-week-old, n=10).

Organ weight

from clipboard

Average weight of the main organs of B-hTSLP/hTSLPR mice plus.

Histopathological analysis

In vivo efficacy of anti-human TSLP antibody in a new mouse asthma model

from clipboard

Analysis of inflammatory cells in BALF by FACS. Mouse asthma model was induced in B-hTSLP/hTSLPR mice and treated with anti-human TSLP antibody (tezepelumab, synthesized in house). BALF was collected at the end of the experiment to detect infiltrated inflammatory cells in lung tissue. The results showed that CD45+ cells, eosinophils and neutrophils in the group (G2) treated with anti-human TSLP antibody decreased significantly when compared with the group (G1) treated with isotype antibody. Values are expressed as mean ± SEM.

In vivo efficacy of anti-human TSLP antibody in a new mouse asthma model

from clipboard

OVA specific IgE in serum and TARC in BALF were significantly reduced in the mouse asthma model treated with anti-TSLP antibody. Serum was collected at the study endpoint. IgE and TARC levels were analyzed by ELISA. The results showed that the levels of OVA specific IgE and TARC in mice treated with tezepelumab (in house) was lower than that in untreated mice. Values are expressed as mean ± SEM. TARC: thymic and activating regulatory chemokine, also known as CCL17 (C-C motif chemokine ligand 17).

In vivo efficacy of anti-human TSLP antibody in a new mouse asthma model

from clipboard

H&E staining of asthma-like model in B-hTSLP/hTSLPR mice plus. Lung tissues were collected at the study endpoint and analyzed with H&E staining. The results showed that compared to the untreated group (G1), the group of mice treated with tezepelumab (in house) showed a significant reduction in inflammatory infiltration and mucus secretion in lung tissue, indicating that B-hTSLP/hTSLPR mice provide a powerful preclinical model for in vivo evaluation of anti-human TSLP antibodies. Black arrow: inflammatory cells; black triangle: eosinophils; asterisk: mucus. Values are expressed as mean ± SEM.

Experimental schedule for Induction of AD-like skin lesions and in vivo efficacy of anti-human TSLP antibody

from clipboard

Experimental schedule for Induction of atopic dermatitis (AD)-like skin lesions and in vivo efficacy of anti-human TSLP antibody in B-hTSLP/hTSLPR mice plus. OXA was applied to ear skin of mice on day 0, and then challenge to the same site of skin nine times from days 7 to 25. Anti-human TSLP antibody tezepelumab (in house) was administered by intraperitoneal injection (n = 6). OXA: oxazolone.

In vivo efficacy of anti-human TSLP antibody in OXA induced AD-like mouse model

from clipboard

Efficacy of anti-human TSLP antibody in B-hTSLP/hTSLPR mice plus. Mice in each group were treated with anti-hTSLP antibody tezepelumab (in house). (A) Statistical analysis of ear thickness in each group. Epidermis of ear began to desquamate from day 18. So the ear thicknesses were decreased from day 18 as shown in figure. (B) Body weight changes during the treatment. (C) Total IgE levels in serum. Serum was collected on day 26 and total IgE levels were measured by ELISA. (n = 6). Values are expressed as mean ± SEM.

H&E staining of ear skin in AD-like mouse model of B-hTSLP/hTSLPR mice plus

from clipboard

Effects of anti-human TSLP antibody on ear skin of the AD mouse model.(A) Hematoxylin and eosin (H&E) staining. (B) Thickness of ear epidermal skin. (C) Score of eosinophils infiltrated in ear epidermal skin.(D) Total score of ear epidermal skin. Ear thickness and infiltration scores of eosinophils in ear skin of the groups treated with Tezepelumab (in house) were decreased significantly compared to that in the isotype control, demonstrating that the B-hTSLP/hTSLPR mice plus provide a powerful preclinical model for in vivo evaluation of anti-human TSLP antibodies. Infiltration score of eosinophils: 1=slight; 2=mild; 3=moderate; 4=severe. The content of the pathology total score evaluation includes the following aspects: epidermal hyperplasia in skin, erosion/crusting, hyperkeratosis and parakeratosis; inflammatory cell infiltration in dermis and subcutaneous. AD: Atopic dermatitis.